Resources Chronic Lymphocytic Leukaemia (CLL)

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

CLL Educational materials video

Date of preparation: August 2023. 0623-BRU-PRC-032

BTK inhibitor choices in CLL: What’s next for zanubrutinib in CLL? – Dr Toby Eyre

Date of preparation: July 2023. 0723-BRU-PRC-081

BRUKINSA® : A next-generation BTK inhibitor – Dr Talha Munir

Date of preparation: August 2023. 0823-BRU-PRC-010

BSH Guidelines: BRUKINSA® in CLL – Dr Renata Walewska

Date of preparation: September 2023. 0923-BRU-PRC-021

When should BRUKINSA® be your BTK inhibitor of choice? – Panel discussion and Q&A

Date of preparation: September 2023. 0923-BRU-PRC-020

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at https://yellowcard.mhra.gov.uk/.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA at www.HPRA.ie.

All adverse events (UK and Ireland) should also be reported to BeiGene at adverse_events@beigene.com; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: medicalinformationEU@beigene.com

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

October 2023 [1023-BRU-PRC-054]

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not